Objective: To determine the association between demographic, lifestyle and medical history factors to Alzheimer's disease (AD), we studied samples of two community dwelling populations with significantly different prevalence rates of AD in Indianapolis, USA (6.24%) and Ibadan, Nigeria (1.4%).
Methods: The samples were drawn from African—American community dwelling residents 65 years of age and over in Indianapolis, and Yoruba community-dwelling residents 65 years of age and over in Ibadan. A two-stage epidemiological design was used in which diagnosis of AD was by National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria.
Results: In Indianapolis, age (odds ratio [OR] = 1.16; 95% confidence interval [Cl] = 1.11-1.21), family history of dementia (OR = 5.40; 95% Cl = 1.99-14.62), low education (0-6 years, OR = 3.49; 95% Cl = 1.06-11.48) and rural residence (OR = 2.49; 95% CI = 1.05-5.88) were associated with a higher risk of AD. In Ibadan, age (OR = 1.15; 95% Cl = 1.12-1.18) and female gender (OR = 13.9; 95% Cl = 3.85-50.28) were associated with a higher risk of AD.
Conclusions: The remarkably similar odds ratios between age and AD between sites suggest that biological processes associated with ageing are essential elements in the development of AD but that genetic and environmental risk factors may alter age-specific rates. In our longitudinal study, we intend to investigate in more depth the interaction between these ageing, genetic and environmental factors.
JormAFKortenAEHendersonASThe prevalance of dementia: a quantative integration of the literature. Acta Psychiatrica Scandinavica1987; 76:465–479.
2.
EvansDAFunkensteinHHAlbertMSPrevalance of Alzheimer's disease in a community population of older persons higher than previously reported. Journal of the Australian Medical Association1989; 262: 2551–2556.
3.
Canadian Study of Health and Aging Working Group.Canadian study of health and aging: study methods and prevalance of dementia. Canadian Medical Association Journal1994; 150:899–913.
4.
PaykelESBrayneCHuppertFAIncidence of dementia in a population older than 75 years in the United Kingdom. Archives of General Psychiatry1994; 51:325–332.
5.
ClassCAUnverzagtFWGaoSJPsychiatric disorders in African–American nursing home residents. American Journal of Psychiatry1996; 153:677–681.
6.
OsuntokunBOHendrieHCOgunniyiAOCross cultural studies in Alzheimer's disease. Ethnicity Disease1992; 2:352–357.
7.
JormAFCross-national comparisons of the occurrence of Alzheimer's and vascular dementias. European Archives of Psychiatry and Clinical Neuroscience1991; 240:218–222.
8.
HendrieHCOsuntokunBOHallKSThe prevelance of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. American Journal of Psychiatry1995; 152:1485–1492.
9.
SchellenbergGDGenetic dissection of Alzheimer's disease, a heterogenous disorder. Proceedings of the National Academy of the United States of America1995; 92:8552–8559.
10.
Van BroeckhovenC.Presenilins and Alzheimer's disease. Nature Genetics1995; 11:230–232.
11.
BlackerDHainesJLRodesLApoE-4 and age at onset of Alzheimer's Disease: the NIMH genetics initiative. Neurology1997; 48:139–147.
12.
Anonymous.Statement of the use of apolipoprotein E testing for Alheimer's Disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer's Disease. Journal of the American Medical Association1995; 274:1627–1629.
13.
HendersonASThe risk factors for Alzheimer's disease: a review and a hypothesis. Acta Psychiatrica Scandinavica1988; 78:257–275.
14.
KukullWALarsonEBBowdenJDSolvent exposure as a risk factor for Alzheimer's disease: a case-control study. American Journal of Epidemiology1995, 141:1059–1079.
15.
Anonymous.The Canadian Study of Health and Aging; risk factors for Alzheimer's disease in Canada. Neurology1994; 44:2073–2080.
16.
GravesABVan DuijnCMChandraVAlcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. International Journal of Epidemiology1991; 20:S58–S61.
17.
HebertLEScherrPABeckettLARelation of smoking and alcohol consumption to incident Alzheimer's disease. American Journal of Epidemiology1992; 135:347–355.
18.
StephensonJ.More evidence links NSAID, estrogen use with reduced Alzheimer's risk. Journal of the American Medical Association1996; 275:1389–1390.
19.
TangMXJacobsDSternYEffect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet1996; 348:429–432.
20.
National Advisory Council on Aging.Report to Congress on the scientific opportunities for developing treatments for Alzheimer's disease. National Advisory Council on Aging, 1995.
21.
HendrieHCHallKSHuiS.Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Annals of Neurology1995; 37:118–120.
22.
MaestreGOttmanRSternYApolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Annals of Neurology1995; 37: 254–259.
23.
OsuntokunBOSahotaAOgunniyiAOLack of an association between Apolipoprotein E ∈4 and Alzheimer's disease in elderly Nigerians. Annals of Neurology1995; 38:463–465.
24.
HallKSOgunniyiAOHendrieHCA cross-cultural community based study of dementias; methods and performance of the survey instrument Indianapolis, U.S.A. and Ibadan, Nigeria. International Journal of Methods in Psychiatry Research1996; 6:129–142.
25.
MorrisJCHeymanAMomRCThe Consortium to Establish a Registry For Alzheimer's Disease (CERAD). Part I. Clinical and neuropyschological assessment of Alzheimer's disease. Neurology1989; 39:149–155.
26.
GurejeOUnverzagtFWOsuntokunBOThe CERAD neuropsychological test battery: norms from a Yoruba-speaking Nigerian sample. West African Journal of Medicine1995; 14:29–33.
27.
UnverzagtFWHallKSTorkeAMEffects of age, education, and gender on CERAD Neuropsychological Test performance in an African American sample. The Clinical Neuropsychologist1996; 10:180–190.
28.
HughesCPBergLDanzigerWLA new clinical scale for the staging of dementia. British Journal of Psychiatry1982; 140:566–572.
29.
McKhannGDrachmanDFolsteinMClinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984; 34:939–944.
30.
SUDAAN.Software for the statistical analysis of correlated data, users manual. Research Triangle Park, NC: Research Triangle Institute, 1996.
31.
PeduzziPConcatoJKemperEHolfordTRFeinsteinARA simulation study of the number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology1996; 49:1373–1379.
32.
DuaraRBarkerWWLopez-AlberolaRAlzheimer's disease: interaction of apolipoprotein E genotypes, family history of dementia, gender, education, ethnicity, and age of onset. Neurology1996; 46:1575–1579.
33.
BarclayLLZemcovABlassJPSansoneJ.Survival in Alzheimer's disease and vascular dementias. Neurology1985; 35:834–840.
34.
BachmanDLWolfPALinnRTIncidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology1993; 43:515–519.
